Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hybrid immunity from SARS-CoV-2 infection and mRNA BNT162b2 vaccine among Thai school-aged children.
Saraban K, Suntarattiwong P, Chantasrisawad N, Boonsathorn S, Kosalaraksa P, Phongsamart W, Tangsathapornpong A, Jaruampornpan P, Srisarang S, Puthanakit T; KIDSVAX study team. Saraban K, et al. Among authors: jaruampornpan p. Vaccine X. 2023 Nov 24;15:100414. doi: 10.1016/j.jvacx.2023.100414. eCollection 2023 Dec. Vaccine X. 2023. PMID: 38090644 Free PMC article.
A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines.
Nanthapisal S, Puthanakit T, Jaru-Ampornpan P, Nantanee R, Sodsai P, Himananto O, Sophonphan J, Suchartlikitwong P, Hiransuthikul N, Angkasekwinai P, Tangsathapornpong A, Hirankarn N; study team. Nanthapisal S, et al. Vaccine. 2022 Apr 20;40(18):2551-2560. doi: 10.1016/j.vaccine.2022.03.036. Epub 2022 Mar 24. Vaccine. 2022. PMID: 35341647 Free PMC article. Clinical Trial.
Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac.
Nantanee R, Aikphaibul P, Jaru-Ampornpan P, Sodsai P, Himananto O, Theerawit T, Sophonphan J, Tovichayathamrong P, Manothummetha K, Laohasereekul T, Hiransuthikul N, Hirankarn N, Puthanakit T; Study Team. Nantanee R, et al. Vaccine. 2022 May 26;40(24):3320-3329. doi: 10.1016/j.vaccine.2022.04.067. Epub 2022 May 2. Vaccine. 2022. PMID: 35513961 Free PMC article.
Immunogenicity and Reactogenicity of mRNA BNT162b2 COVID-19 Vaccine among Thai Adolescents with Chronic Diseases.
Chantasrisawad N, Puthanakit T, Tangsathapornpong A, Techasaensiri C, Phongsamart W, Suwanpakdee D, Jaruampornpan P, Sophonphan J, Suntarattiwong P, Chotpitayasunondh T; Study Team. Chantasrisawad N, et al. Among authors: jaruampornpan p. Vaccines (Basel). 2022 May 29;10(6):871. doi: 10.3390/vaccines10060871. Vaccines (Basel). 2022. PMID: 35746478 Free PMC article.
Immunogenicity to SARS-CoV-2 Omicron variant among school-aged children with 2-dose of inactivated SARS-CoV-2 vaccines followed by BNT162b2 booster.
Chantasrisawad N, Puthanakit T, Kornsitthikul K, Jaru-Ampornpan P, Tawan M, Matapituk P, Sophonphan J, Anugulruengkitt S, Tangsathapornpong A, Katanyutanon A; KIDSBOOST study team*. Chantasrisawad N, et al. Vaccine X. 2022 Sep 30;12:100221. doi: 10.1016/j.jvacx.2022.100221. eCollection 2022 Dec. Vaccine X. 2022. PMID: 36213592 Free PMC article.
The immunogenicity of an extended dosing interval of BNT162b2 against SARS-CoV-2 Omicron variant among healthy school-aged children, a randomized controlled trial.
Chantasrisawad N, Techasaensiri C, Kosalaraksa P, Phongsamart W, Tangsathapornpong A, Jaru-Ampornpan P, Sophonphan J, Suntarattiwong P, Puthanakit T; KIDSVAX study team. Chantasrisawad N, et al. Int J Infect Dis. 2023 May;130:52-59. doi: 10.1016/j.ijid.2023.02.017. Epub 2023 Feb 24. Int J Infect Dis. 2023. PMID: 36841501 Free PMC article. Clinical Trial.
Immunogenicity and Safety of the Third Booster Dose with mRNA-1273 COVID-19 Vaccine after Receiving Two Doses of Inactivated or Viral Vector COVID-19 Vaccine.
Tangsathapornpong A, Nanthapisal S, Pontan K, Bunjoungmanee P, Neamkul Y, Boonyarangkul A, Wanpen S, Fukpho W, Jitpokasem S, Tharabenjasin P, Jaru-Ampornpan P. Tangsathapornpong A, et al. Vaccines (Basel). 2023 Feb 27;11(3):553. doi: 10.3390/vaccines11030553. Vaccines (Basel). 2023. PMID: 36992137 Free PMC article.
54 results